These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 11714817)

  • 61. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The absence of IFN-gamma leads to increased Th2 responses after influenza A virus infection characterized by an increase in CD4+ but not CD8+ T cells producing IL-4 or IL-5 in the lung.
    Wohlleben G; Erb KJ
    Immunol Lett; 2004 Sep; 95(2):161-6. PubMed ID: 15388256
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression.
    Faghih Z; Rezaeifard S; Safaei A; Ghaderi A; Erfani N
    Iran J Immunol; 2013 Dec; 10(4):193-204. PubMed ID: 24375061
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human immunodeficiency virus-1 infection protects against a Tc1-to-Tc2 shift in CD8(+) T cells.
    Gulzar N; Diker B; Balasubramanian S; Jiang JQ; Copeland KF
    Hum Immunol; 2011 Nov; 72(11):995-1000. PubMed ID: 21920400
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen.
    Wizel B; Starcher BC; Samten B; Chroneos Z; Barnes PF; Dzuris J; Higashimoto Y; Appella E; Sette A
    J Immunol; 2002 Sep; 169(5):2524-35. PubMed ID: 12193722
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells.
    Wang B; Maile R; Greenwood R; Collins EJ; Frelinger JA
    J Immunol; 2000 Feb; 164(3):1216-22. PubMed ID: 10640733
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts.
    Diamond AS; Gill RG
    J Immunol; 2000 Jul; 165(1):247-55. PubMed ID: 10861058
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
    Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
    J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes.
    Boni A; Iezzi G; Degl'Innocenti E; Grioni M; Jachetti E; Camporeale A; Bellone M
    Eur J Immunol; 2006 Dec; 36(12):3157-66. PubMed ID: 17111344
    [TBL] [Abstract][Full Text] [Related]  

  • 77. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Strong TCR signaling, TLR ligands, and cytokine redundancies ensure robust development of type 1 effector T cells.
    Nembrini C; Abel B; Kopf M; Marsland BJ
    J Immunol; 2006 Jun; 176(12):7180-8. PubMed ID: 16751361
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
    Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
    J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.